Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia - 25/08/11
, K. Arnold Faught, MD, FRCP(C), Jennifer Vethamuthu, MD, Margaret L. Lawson, MD, MSc, FRCP(C)
Reprint requests: Sarah E. Lawrence, Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON Canada K1H 8L1.Abstract |
Objectives |
To assess the efficacy of the anti-estrogens tamoxifen and raloxifen in the medical management of persistent pubertal gynecomastia.
Study design |
Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).
Results |
Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.
Conclusion |
Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : BMI, DHT, LH
Mappa
Vol 145 - N° 1
P. 71-76 - luglio 2004 Ritorno al numero
Articolo precedente
- Duration of intubation attempts during Neonatal Resuscitation
- Brian Lane, Neil Finer, Wade Rich
- Lipid abnormalities in children with types A and B Niemann Pick disease
- Margaret M. McGovern, Tilla Pohl-Worgall, Richard J. Deckelbaum, William Simpson, David Mendelson, Robert J. Desnick, Edward H. Schuchman, Melissa P. Wasserstein
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?